elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35527067-838C2CEE-C2FC-4BD4-B82D-2EF6EBC05552
Q35527067-838C2CEE-C2FC-4BD4-B82D-2EF6EBC05552
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35527067-838C2CEE-C2FC-4BD4-B82D-2EF6EBC05552
Endpoint selection and relative (versus absolute) risk reporting in published medication trials.
P2860
Q35527067-838C2CEE-C2FC-4BD4-B82D-2EF6EBC05552
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35527067-838C2CEE-C2FC-4BD4-B82D-2EF6EBC05552
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7277e9615489ede4d11526173f8f1d67f1796b71
P2860
Surrogate end points in clinical trials: are we being misled?